Paper Details

  1. Home
  2. Paper Details

Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome.

Author: BruzzeseEugenia, GuarinoAlfredo, PesceMarcella, SarnelliGiovanni

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Rifaximin, a poorly absorbable antibiotic, is a suitable treatment for IBS-D, in both adults and children.
Paper Details　
Original Abstract of the Article :
Rifaximin is a poorly absorbable antibiotic with a broad-spectrum activity against both Gram-negative and -positive bacteria. It is active in the small intestine due to its high bile solubility, whereas in the aqueous environment of the colon, it shows limited efficacy against highly susceptible bac...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/17425255.2018.1488964

データ提供：米国国立医学図書館（NLM）

Pharmacokinetic Drug Evaluation of Rifaximin for Treatment of Diarrhea-Predominant Irritable Bowel Syndrome

The field of [irritable bowel syndrome (IBS) treatment] is constantly searching for effective and safe therapies. This review focuses on [rifaximin, a poorly absorbable antibiotic] for the treatment of [diarrhea-predominant IBS (IBS-D)]. The review highlights the unique pharmacokinetic properties of rifaximin, which [target gut bacteria] without significant systemic effects. It concludes that [rifaximin is a suitable treatment option for IBS-D] in both adults and children.

The Potential of Rifaximin for IBS-D Treatment

This review suggests that [rifaximin] may be an effective and safe treatment for [IBS-D] due to its [ability to modulate gut microbiota] without causing significant systemic side effects. The review highlights its [potential benefit] in correcting gut microflora imbalances that contribute to IBS-D symptoms.

Finding Relief from IBS-D Symptoms

For individuals suffering from [IBS-D], this review offers hope for a [potential treatment option]. While [rifaximin] is not a cure, it shows promise for [managing symptoms] and improving quality of life for patients. It's essential to [consult with a healthcare professional] to determine the best treatment approach for your individual needs.

Dr.Camel's Conclusion

Just as a camel's digestive system is adapted to thrive in the harsh desert environment, the gut microbiome plays a crucial role in our overall health. This review encourages us to explore the potential of [targeted gut microbiome modulation] with rifaximin as a therapeutic strategy for IBS-D.

Date :
  1. Date Completed 2018-07-06
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

29897844

DOI: Digital Object Identifier

10.1080/17425255.2018.1488964

Related Literature

Article Analysis
・Side Effects of rifaximin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.